# Five Messengers, Five Different Wires

> Compare Semaglutide, Ipamorelin, GHK-Cu, PT-141, and MOTS-c — Peptide Messengers — A side-by-side comparison of five research peptide messengers — semaglutide, ipamorelin, GHK-Cu, PT-141, and MOTS-c — across receptor mechanism, evidence maturity, regulatory status, and the leading caution for each.

**RESEARCH PEPTIDE FUNDAMENTALS / MATRIX**

How a gut-hormone mimic, a pituitary trigger, a copper carrier, a brain-circuit agonist, and a mitochondrial signal differ in mechanism, evidence, and regulatory standing.

## The short version

This page lines up [semaglutide](/semaglutide), [ipamorelin](/ipamorelin), [GHK-Cu](/ghk-cu), [PT-141](/pt-141), and [MOTS-c](/mots-c) on the dimensions that actually distinguish them: what receptor or pathway each one signals through, where the strongest evidence for each comes from, and what a reader most needs to know before taking any of it seriously. The headline is that "chemical messenger" is a shared mechanism, not a shared risk profile or a shared evidence base — the five compounds range from a decade-deep outcome-trial record to a single Phase 2 trial that missed its endpoint to a peptide that has never been given to a human in a controlled trial at all. Nothing on this page is a recommendation to use any of these compounds, and no dose is implied anywhere.

## Mechanism and messenger type

| Compound | Receptor / pathway | What it signals | Signal source it mimics |
|---|---|---|---|
| Semaglutide | GLP-1 receptor (GLP-1R) | Fullness, slowed digestion, insulin release | A natural gut hormone released after eating |
| Ipamorelin | Ghrelin receptor (GHS-R1a) | A single pulse of growth hormone from the pituitary | The hunger hormone ghrelin's receptor |
| GHK-Cu | Fibroblast signaling + copper delivery | Collagen, elastin, and tissue-repair gene programs | A tripeptide already present in human plasma |
| PT-141 | Melanocortin receptors (MC4R, MC3R) | Central sexual desire and arousal circuits | A pituitary/hypothalamic pigment-and-appetite hormone (alpha-MSH) |
| MOTS-c | AMPK activation via folate-cycle inhibition; nuclear gene regulation | Cellular stress and metabolic adaptation | The mitochondrion's own encoded stress signal |

## Evidence maturity

| Compound | Strongest evidence | Human trial status |
|---|---|---|
| Semaglutide | Multiple large Phase 3 outcome trials across weight, cardiovascular, and kidney endpoints [1][3][4] | FDA-approved, multiple indications |
| Ipamorelin | One small acute-dosing pharmacokinetic study; a single Phase 2 trial that missed its primary endpoint [10][11] | Never approved; no ongoing indication trials |
| GHK-Cu | Multiple placebo-controlled topical dermatology trials and one combination hair-growth RCT [13][15][16] | Cosmetic ingredient only; no injectable approval |
| PT-141 | Two Phase 3 trials plus a 52-week open-label extension [20][21] | FDA-approved for one specific indication |
| MOTS-c | Mouse and cell studies, plus one human observational biomarker cohort [23][24][26][27] | No completed human efficacy trial of any kind |

Read top to bottom, this table is close to a ranking of evidence maturity: semaglutide and PT-141 anchor the approved end with outcome and pivotal trials behind them; GHK-Cu sits in the middle with real but topical-only human data; ipamorelin has a single negative human trial; MOTS-c has none at all in humans as an intervention, only as an observed biomarker.

## Regulatory status and the one caution that matters most

| Compound | FDA status | The single biggest caution |
|---|---|---|
| Semaglutide | Approved (diabetes, weight management, cardiovascular risk, MASH) | Gastrointestinal intolerance is the leading cause of stopping treatment [5] |
| Ipamorelin | Never approved for any indication | No long-term human safety data exist beyond one short surgical trial [10] |
| GHK-Cu | Cosmetic ingredient approved; injectable/oral use is unapproved | Systemic (non-topical) use has no validated human safety basis |
| PT-141 | Approved only for HSDD in premenopausal women | Approved for one narrow population; all other use is off-label [22] |
| MOTS-c | Not approved for any human use | No human pharmacokinetic or efficacy data exist to guide anything |

Across all five, one caution repeats regardless of mechanism: material described as a "research chemical" or sold outside a pharmacy sits entirely outside pharmaceutical quality control, and none of these compounds' cited research supports a specific human dose outside the context of the studies where it was measured.

---

A reading desk for the body's own chemical signaling — not a clinic, not a vendor, and never the source of a dose.